KPV vs BPC-157 — Anti-Inflammatory vs Tissue Repair
KPV and BPC-157 both show up in gut and recovery research and are sold as a combined blend, but no combination trial of the two exists. This page reports what each compound is, which studies apply to which compound, and the evidence level for each.
On this page
Molecule Identity
KPV is the C-terminal tripeptide (residues 11-13) of α-melanocyte-stimulating hormone (α-MSH). Despite that shared origin, KPV does not activate melanocortin receptors — the fragment lacks the receptor-binding domain, and its reported anti-inflammatory activity acts intracellularly through NF-κB inhibition instead. BPC-157 is a synthetic 15-amino-acid peptide based on a protein found in human gastric juice.
| KPV | BPC-157 | |
|---|---|---|
| What it is | Synthetic tripeptide (Lys-Pro-Val), the C-terminal fragment of the hormone α-MSH | Synthetic 15-amino-acid gastric pentadecapeptide, based on a protein in gastric juice |
| Proposed mechanism | NF-κB nuclear translocation inhibition, reducing pro-inflammatory cytokines; taken into gut epithelium via the PepT1 transporter | Angiogenesis (VEGF/eNOS), EGR-1-mediated growth-factor signaling, FAK-paxillin pathway |
| Human evidence | None identified | Lee & Padgett 2021 (PMID 34324435) — retrospective case series, intra-articular knee injection |
| Animal evidence | Kannengiesser et al. 2008 (PMID 18092346) — mouse DSS and CD45RBhi-transfer colitis models | Multiple rodent studies, including Biçer et al. 2026 (PMID 42542926), rat Achilles-tendon model |
| Evidence level | Animal Model | Human Observational |
| FDA status | Not FDA-approved; FDA lists it as nominated but withdrawn (previously Category 2), not in Category 1 | Not FDA-approved; FDA lists it as nominated but withdrawn (previously Category 2), not in Category 1 |
The figures in the rows above come from different studies, different species, and (for BPC-157) a route of administration (intra-articular injection) different from the subcutaneous or oral routes KPV research typically uses.
Human Evidence, by Molecule
No human trial of KPV has been identified. Community-reported oral, subcutaneous, and topical use in humans is reported practice, not a trial finding, and is not derived from either cited animal study's own numbers.
BPC-157's human evidence is Lee & Padgett 2021 (Altern Ther Health Med, PMID 34324435), a retrospective chart review of 17 patients who received an intra-articular knee injection of BPC-157 at 4 mg. This is Human Observational evidence — a retrospective, uncontrolled case series, not a randomized trial — and its route (intra-articular) is specific to that study; it does not establish evidence for the subcutaneous or oral routes more commonly discussed for gut applications.
Animal Evidence
Kannengiesser et al. 2008 (Inflamm Bowel Dis, PMID 18092346) treated mice with KPV in two colitis models — DSS-induced colitis and CD45RBhi transfer colitis — reporting earlier recovery, greater body-weight regain, and significantly reduced histological inflammation and colonic myeloperoxidase activity versus untreated controls. The paper's methods section, which would report the exact administered dose, is paywalled beyond the abstract; Prof. Peptide has not independently verified the numeric dose. Xiao et al. 2017 (Mol Ther, PMID 28143741) separately delivered KPV orally to mice with induced ulcerative colitis using a nanoparticle/hydrogel delivery system, reporting reduced mucosal damage and TNF-α downregulation.
BPC-157's animal evidence includes Biçer et al. 2026 (PMID 42542926), a rat Achilles-tendon-transection model, among other rodent studies on the BPC-157 profile page.
Adverse events reported in the cited studies
Kannengiesser et al. 2008 reported no adverse findings for KPV in either mouse colitis model in the paper's own results. Lee & Padgett 2021 reported no serious adverse events in its 17-patient BPC-157 case series.
Evidence Level
KPV: Animal Model (Kannengiesser et al. 2008, PMID 18092346, mouse colitis). BPC-157: Human Observational (Lee & Padgett 2021, PMID 34324435 — intra-articular knee injection, not the subcutaneous or oral routes more commonly discussed for gut applications). Full profiles, including each compound's wider citation list, are on the KPV and BPC-157 profile pages.
FAQ
Are KPV and BPC-157 the same compound?
No — they are different molecules. KPV is a three-amino-acid fragment of the hormone α-MSH. BPC-157 is a fifteen-amino-acid gastric pentadecapeptide. They differ in proposed mechanism — KPV is reported as anti-inflammatory (NF-κB inhibition), BPC-157 as regenerative (angiogenesis and growth-factor signaling).
Does either compound have human trial evidence?
BPC-157's one identified human study is Lee & Padgett 2021 (PMID 34324435), a retrospective case series using intra-articular (knee-joint) injection — Human Observational evidence, not a randomized trial, and specific to that route. No human trial of KPV was identified for this page; its evidence is Animal Model.
What did the cited KPV animal study actually find?
Kannengiesser et al. 2008 (Inflamm Bowel Dis, PMID 18092346) treated mice in two colitis models — DSS-induced colitis and CD45RBhi transfer colitis — and reported earlier recovery, greater body-weight regain, and significantly reduced histological inflammation and colonic myeloperoxidase activity versus untreated controls, with no adverse findings reported in the paper's own results. The paper's methods section, which would give the exact administered dose, sits behind a paywall beyond the abstract; Prof. Peptide has not independently verified the numeric dose, so none is stated on this page.
Is there a trial that tested KPV and BPC-157 together?
No combination trial of KPV and BPC-157 was identified. The two are sold together as a KPV + BPC-157 blend, but there is no established combination protocol backed by a trial, and the human evidence for each compound individually is limited.
References
- Brzoska T, Luger TA, Maaser C, Schiller M, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives. Endocr Rev. 2008;29(5):581-602. https://pubmed.ncbi.nlm.nih.gov/18612139/
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. https://pubmed.ncbi.nlm.nih.gov/18092346/
- Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640.
- Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. https://pubmed.ncbi.nlm.nih.gov/34324435/
- Biçer O, Adanir O, Güleryüz Y, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. https://pubmed.ncbi.nlm.nih.gov/42542926/
Have a question about KPV vs BPC-157 — Evidence, Mechanism, and Molecule Identity? Send us an email